Nephros (NEPH) vs Stereotaxis (STXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nephros (NEPH) has outperformed Stereotaxis (STXS) over the past year, losing 36.2% versus a loss of 68.9%. Over five years, NEPH leads with a -57.6% price change compared with -81.3% for STXS. Stereotaxis is the larger company by market cap ($111.2 million vs $35.7 million), about 3.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NEPH | STXS |
|---|---|---|
| Share price | $3.29 | $1.11 |
| Market cap | $35.73M | $111.22M |
| 1-day change | +2.81% | -1.77% |
| YTD return | -32.58% | -51.74% |
| 1-year return | -36.24% | -68.91% |
| 5-year return | -57.60% | -81.28% |
| P/E ratio (TTM) | 21.93 | — |
| Forward P/E | 15.67 | — |
| EPS (TTM) | $0.15 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.42 | $3.42 |
| 52-week low | $2.66 | $1.09 |
| Distance from 52-week high | -48.75% | -67.54% |
| Analyst consensus | none | none |
| Avg. price target upside | +89.97% | +170.27% |
| Average volume | 27.59K | 808.41K |
| Shares outstanding | 10.86M | 100.20M |
| Employees | 36 | 131 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Medical Instruments & Supplies |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Stereotaxis is about 3.1 times larger than Nephros by market value ($111.22M vs $35.73M).
- NEPH has outperformed STXS by 32.7 percentage points over the past year.
About Nephros
NEPH stock →Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities.
Healthcare · Medical Instruments & Supplies · 36 employees
About Stereotaxis
STXS stock →Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
Healthcare · Medical Instruments & Supplies · 131 employees
NEPH vs STXS FAQ
Which is bigger, Nephros or Stereotaxis?
Stereotaxis (STXS) is larger, with a market capitalization of $111.22M compared with $35.73M for Nephros (NEPH).
Which stock has performed better over the past year, NEPH or STXS?
NEPH returned -36.24% over the past 12 months, compared with -68.91% for STXS (price return, excluding dividends). Past performance does not predict future results.
Are Nephros and Stereotaxis in the same industry?
Yes. Both are classified in the Medical Instruments & Supplies industry within the Healthcare sector.